BIOCRYST PHARMACEUTICALS, INC. Inventory, Gross
BIOCRYST PHARMACEUTICALS, INC. (BCRX) had Inventory, Gross of $39.17 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Inventory, Gross
us-gaap:InventoryGross · last filed 2026-08-05
- 2026-06-30: Inventory, Gross $39.17M.
- 2026-03-31: Inventory, Gross $34.96M.
- 2025-12-31: Inventory, Gross $30.16M.
- 2025-09-30: Inventory, Gross $30.28M.
| Period end | Inventory, Gross |
|---|---|
| 2026-06-30 | $39.17M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $34.96M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $30.16M 10-Q · filed 2026-08-05 |
| 2025-09-30 | $30.28M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $29.16M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $34.05M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $33.92M 10-K · filed 2026-02-26 |
| 2024-09-30 | $31.94M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $30.57M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $31.38M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $30.28M 10-K · filed 2025-02-25 |
| 2023-09-30 | $30.98M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $28.45M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $28.88M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $28.71M 10-K · filed 2024-02-27 |
| 2022-09-30 | $27.26M 10-Q · filed 2022-11-04 |
| 2022-06-30 | $23.63M 10-Q · filed 2022-08-05 |
| 2022-03-31 | $16.40M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $16.04M 10-K · filed 2023-02-27 |
| 2021-09-30 | $14.09M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $10.12M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $5.38M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $7.31M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |